RSS
Biofarm recorded a net profit of 21.442 million lei
Pharmaceutical producer Biofarm recorded, after the first three quarters of 2014, a net profit of 21.442 million lei, up by 15.53% from that recorded in the same period of last year, 18,560 million lei respectively.
The company's sale revenues amounted to 89,480 million lei, by almost 5% higher compared to those reported on September 30, 2013 (85.571 million lei).
The staff-related costs also increased in the first nine months of 2014, by almost 4%, having stood at 13.269 million lei, compared to 12.781 million lei in the same period in 2013.
On September 30, 2014, the company had stockpiles worth 19.692 million lei, and the commercial and similar receivables were reduced to 45.960 million lei, from 64.678 million lei. Trade and similar debts decreased as well, in the first nine months of 2014, to 25.717 million lei, from 30.282 million lei on December 31, 2013.
Biofarm is one of the leading Romanian pharmaceutical and dietary supplements producers. Currently, the company is one of the top ten producers operating on the Romanian pharmaceutical market, a dynamic and a very competitive one.
Biofarm has over 200 products covering 61 therapeutic areas' portfolio.
With a stable position on the Romanian pharmaceutical market, Biofarm aims to improve its position also on the international market. Currently, Biofarm is present in ten countries: Armenia, Azerbaijan, Belarus, Kazakhstan, Lithuania, Republic of Moldova, Mongolia, Russia, Ukraine, Hungary and its expansion is continuing.